Literature DB >> 8911010

Serum antibacterial and antitoxin responses in clinical cholera caused by Vibrio cholerae O139 Bengal and evaluation of their importance in protection.

R K Nandy1, M J Albert, A C Ghose.   

Abstract

Vibrio cholerae O139 Bengal strain was the causative agent of the recent epidemics of cholera in India and Bangladesh. We studied antibacterial and antitoxin immune responses in acute and convalescent phase paired sera collected from seven of these cholera patients. Significant rise in the levels of both antibacterial and antitoxin antibodies was demonstrable in the sera of convalescent cholera patients. Antibacterial antibodies, directed primarily against O139 lipopolysaccharides (LPS), belonged to IgM class, while antitoxin antibodies were of IgG and IgA class and neutralized cholera toxin. The convalescent sera, however, showed no increase in the reactivity towards V. cholerae O1 whole cells or their LPS preparation. Immunoblotting experiments revealed that the convalescent, but not the acute, phase serum recognized the truncated form of LPS characteristics of O139 strains. Convalescent serum also induced definite protection against O139, but not O1, challenge in experimental animal model. Further studies showed that such protection was probably mediated by antibodies inhibiting intestinal colonization of O139 organisms. These results suggest that critical difference(s) exists between the immunogenic somatic components of V. cholerae O1 and O139 organisms that are of considerable importance in protection against cholera.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8911010     DOI: 10.1016/0264-410x(96)00035-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Evaluation of synthetic schemes to prepare immunogenic conjugates of Vibrio cholerae O139 capsular polysaccharide with chicken serum albumin.

Authors:  Z Kossaczka; S C Szu
Journal:  Glycoconj J       Date:  2000-06       Impact factor: 2.916

2.  Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid.

Authors:  A Boutonnier; S Villeneuve; F Nato; B Dassy; J M Fournier
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

3.  Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice.

Authors:  Z Kossaczka; J Shiloach; V Johnson; D N Taylor; R A Finkelstein; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

4.  Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria.

Authors:  J F Viret; D Favre; B Wegmüller; C Herzog; J U Que; S J Cryz; A B Lang
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

Review 5.  Immune responses to cholera in children.

Authors:  Daniel T Leung; Fahima Chowdhury; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Journal:  Expert Rev Anti Infect Ther       Date:  2012-04       Impact factor: 5.091

6.  Establishment of an adult mouse model for direct evaluation of the efficacy of vaccines against Vibrio cholerae.

Authors:  E Nygren; B-L Li; J Holmgren; S R Attridge
Journal:  Infect Immun       Date:  2009-05-26       Impact factor: 3.441

7.  Safety and immunogenicity of a live oral recombinant cholera vaccine VA1.4: a randomized, placebo controlled trial in healthy adults in a cholera endemic area in Kolkata, India.

Authors:  Suman Kanungo; Bandana Sen; Thandavarayan Ramamurthy; Dipika Sur; Byomkesh Manna; Gururaja P Pazhani; Goutam Chowdhury; Puja Jhunjhunwala; Ranjan K Nandy; Hemanta Koley; Mihir Kumar Bhattacharya; Sanjay Gupta; Gaurav Goel; Bindu Dey; Thungapathra M; G Balakrish Nair; Amit Ghosh; Dilip Mahalanabis
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

8.  Immunogenicity of a bivalent killed thimerosal-free oral cholera vaccine, Euvichol, in an animal model.

Authors:  Eun Young Lee; Sena Lee; Semi Rho; Jae-Ouk Kim; Seuk Keun Choi; Young Jin Lee; Joo Young Park; Manki Song; Jae Seung Yang
Journal:  Clin Exp Vaccine Res       Date:  2018-07-31

9.  IgM specific to lipopolysaccharide of Vibrio cholerae is a surrogate antibody isotype responsible for serum vibriocidal activity.

Authors:  Jae Seung Yang; So Jung An; Mi Seon Jang; Manki Song; Seung Hyun Han
Journal:  PLoS One       Date:  2019-03-07       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.